Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (251-260 of 280) with videos related to

Pageof 28
Sort By:
Nature Medicine|June 24, 2024
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trialToru Mukohara, Yeon Hee Park, David Sommerhalder, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid TumorsPatricia M LoRusso, Jing Li, Angelika Burger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2021
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research WorkshopDaniel D Von Hoff, Gary M Clark, Charles A Coltman, et al.
Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.
Thyroid : Official Journal of the American Thyroid Association|June 16, 2020
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid CancerKeith C Bible, Michael E Menefee, Chia-Chi Josh Lin, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Plos One|April 7, 2021
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trialPatricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, et al.
The European Physical Journal. C, Particles and Fields|May 9, 2025
Reweighting simulated events using machine-learning techniques in the CMS experimentA Hayrapetyan, A Tumasyan, W Adam, et al.
Pageof 28

Showing results (251-260 of 280) with videos related to

Sort By:
Pageof 28
Nature Medicine|June 24, 2024
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trialToru Mukohara, Yeon Hee Park, David Sommerhalder, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid TumorsPatricia M LoRusso, Jing Li, Angelika Burger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2021
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research WorkshopDaniel D Von Hoff, Gary M Clark, Charles A Coltman, et al.
Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.
Thyroid : Official Journal of the American Thyroid Association|June 16, 2020
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid CancerKeith C Bible, Michael E Menefee, Chia-Chi Josh Lin, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Plos One|April 7, 2021
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trialPatricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, et al.
The European Physical Journal. C, Particles and Fields|May 9, 2025
Reweighting simulated events using machine-learning techniques in the CMS experimentA Hayrapetyan, A Tumasyan, W Adam, et al.
Pageof 28